Clinical Trials Logo

Clinical Trial Summary

This is a prospective cross-sectional, observational, single-center study of Alport patients, in which a single, first morning voided urine collection will be acquired and used to validate assays of urine biomarkers that reflect changes in glomerular protein filtration barrier function.

The purpose of this study is to identify biomarkers indicative of changes in glomerular filtration function that occur during the course of proteinuric renal diseases such as Alport nephropathy.


Clinical Trial Description

n/a


Study Design

Observational Model: Cohort, Time Perspective: Cross-Sectional


Related Conditions & MeSH terms


NCT number NCT01602835
Study type Observational
Source Novartis
Contact
Status Terminated
Phase N/A
Start date September 2012
Completion date May 2013

See also
  Status Clinical Trial Phase
Completed NCT01696253 - Multi-center Controlled Clinical Trials in Alport Syndrome-A Feasibility Study
Recruiting NCT00481130 - Alport Syndrome Treatments and Outcomes Registry
Recruiting NCT05687474 - Baby Detect : Genomic Newborn Screening
Recruiting NCT06065852 - National Registry of Rare Kidney Diseases
Recruiting NCT05448755 - A Study of ELX-02 in Patients With Alport Syndrome Phase 2
Recruiting NCT06274489 - A Study to Evaluate Setanaxib in Patients With Alport Syndrome Phase 1/Phase 2
Terminated NCT02855268 - Study of Lademirsen (SAR339375) in Patients With Alport Syndrome Phase 2
Recruiting NCT06226896 - Effects of Dapagliflozin on Progression of Alport Syndrome
Recruiting NCT05927467 - Eurbio-Alport (RaDiCo Cohort) (RaDiCo Eurbio-Alport)
Terminated NCT03749447 - An Extended Access Program for Bardoxolone Methyl in Patients With CKD (EAGLE) Phase 3
Completed NCT03019185 - A Phase 2/3 Trial of the Efficacy and Safety of Bardoxolone Methyl in Patients With Alport Syndrome - CARDINAL Phase 2/Phase 3
Completed NCT01705132 - Urinary Biomarkers of the Progression of Alport Kidney Disease N/A
Recruiting NCT05267262 - Study to Evaluate R3R01 in Patients With Alport Syndrome and Patients With Focal Segmental Glomerulosclerosis Phase 2
Completed NCT00622544 - A Prospective Study of Microalbuminuria in Untreated Boys With Alport Syndrome
Recruiting NCT02378805 - European Alport Therapy Registry - European Initiative Towards Delaying Renal Failure in Alport Syndrome
Not yet recruiting NCT05655728 - Treatment With Metformin in Chinese Children With Alport Syndrome Phase 4
Completed NCT00309257 - Effects of an Intensified Treatment With ACE-I,ATA II and Statins in Alport Syndrome Phase 2
Not yet recruiting NCT05133050 - Safety and Efficacy of ACEI in Alport Syndrome Patients With COL4A3/COL4A4/COL4A5 Variants N/A
Recruiting NCT04947813 - Genotype-Phenotype Correlations in Patients With Alport Syndrome
Active, not recruiting NCT04573920 - Atrasentan in Patients With Proteinuric Glomerular Diseases Phase 2